Champignon Receives DTC Eligibility
April 17 2020 - 12:01PM
Champignon Brands Inc. (“
Champignon” or the
“
Company”)
(CSE: SHRM) (FWB: 496) (OTC:
SHRMF), a human optimization sciences company focused on
applying novel and natural treatment protocols to address a broad
range of disorders and deficiencies with an emphasis on psychedelic
medicine, is pleased to announce its common shares are now eligible
for electronic clearing and settlement through the Depository Trust
Company (DTC). DTC is a subsidiary of the Depository Trust &
Clearing Corp. (DTCC) that manages the electronic clearing and
settlement of publicly traded companies in the United States.
Champignon’s common shares are now fully DTC
eligible and will continue to trade under the ticker symbol “SHRMF”
on the OTC Markets. Through an electronic method of clearing
securities, DTC eligibility simplifies the process of trading and
transferring the Company's common shares between brokerages in the
United States.
“We are actively engaged in pursuing new avenues of
distribution both in North America and internationally, in order to
enhance the ability of larger audiences to participate in the
Champignon story, as well as broaden our already robust shareholder
base,” commented Gareth Birdsall, CEO of Champignon. “With the
receipt of DTC eligibility, our common shares will become
accessible to United States investors, both retail and
institutional - the jurisdiction where many of the important
initiatives in psychedelic medicine are emanating and where the
Company plans to roll out new clinical entities within significant
urban population centres."
About Champignon Brands Inc.
Champignon Brands Inc. (CSE: SHRM) is a
research-driven company specializing in the formulation of a suite
of medicinal mushrooms health products as well as novel ketamine,
anaesthetics and adaptogenic delivery platforms for the
nutritional, wellness and alternative medicine industries. Via its
vertically integrated alternative medicine product range,
Champignon is pursuing the development and commercialization of
rapid onset treatments capable of improving health outcomes, such
as depression and post-traumatic stress disorder (PTSD), as well as
substance and alcohol use disorders. Under a collaborative research
agreement with the University of Miami's Miller School of Medicine,
the Company is conducting preclinical studies and eventual human
clinical trials, with the objective of demonstrating safety and
efficacy of the combination of psilocybin and cannabidiol in
treating mTBI with PTSD or stand-alone PTSD. Champignon continues
to be inspired by sustainability, as its medicinal mushroom-infused
SKUs are organic, non-GMO and vegan certified. For more
information, visit the Company’s website at:
https://champignonbrands.com/.
ON BEHALF OF THE BOARD OF DIRECTORS
W. Gareth Birdsall CEO & DirectorT:
+1 (613) 967-9655E: info@champignonbrands.com
FOR INVESTOR INQUIRIES:
Tyler Troup Circadian Group
E: SHRM@champignonbrands.com
FOR CHAMPIGNON BRANDS FRENCH INQUIRIES:
Remy ScalabriniMaricom Inc.E: rs@maricom.ca T:
(888) 585-MARI
The CSE and Information Service Provider have not
reviewed and does not accept responsibility for the accuracy or
adequacy of this release.
Forward-looking Information Cautionary
Statement
Except for statements of historic fact, this news
release contains certain "forward-looking information" within the
meaning of applicable securities law. Forward-looking information
is frequently characterized by words such as "plan", "expect",
"project", "intend", "believe", "anticipate", "estimate" and other
similar words, or statements that certain events or conditions
"may" or "will" occur. Forward-looking statements are based on the
opinions and estimates at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors
that could cause actual events or results to differ materially from
those anticipated in the forward-looking statements including, but
not limited to delays or uncertainties with regulatory approvals,
including that of the CSE. There are uncertainties inherent in
forward-looking information, including factors beyond the Company’s
control. There are no assurances that the business plans for
Champignon Brands described in this news release will come into
effect on the terms or time frame described herein. The Company
undertakes no obligation to update forward-looking information if
circumstances or management's estimates or opinions should change
except as required by law. The reader is cautioned not to place
undue reliance on forward-looking statements. Additional
information identifying risks and uncertainties that could affect
financial results is contained in the Company’s filings with
Canadian securities regulators, which are available at
www.sedar.com.
Champignon Brands (CSE:SHRM)
Historical Stock Chart
From Jul 2024 to Aug 2024
Champignon Brands (CSE:SHRM)
Historical Stock Chart
From Aug 2023 to Aug 2024